These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 15165271

  • 1. Significance of atypia in conventional Papanicolaou smears and liquid-based cytology: a follow-up study.
    Schledermann D, Ejersbo D, Hoelund B.
    Cytopathology; 2004 Jun; 15(3):148-53. PubMed ID: 15165271
    [Abstract] [Full Text] [Related]

  • 2. Improvement of diagnostic accuracy and screening conditions with liquid-based cytology.
    Schledermann D, Ejersbo D, Hoelund B.
    Diagn Cytopathol; 2006 Nov; 34(11):780-5. PubMed ID: 17041948
    [Abstract] [Full Text] [Related]

  • 3. ThinPrep Pap Test promotes detection of glandular lesions of the endocervix.
    Bai H, Sung CJ, Steinhoff MM.
    Diagn Cytopathol; 2000 Jul; 23(1):19-22. PubMed ID: 10907926
    [Abstract] [Full Text] [Related]

  • 4. [Applicative aspects of liquid-based cytology in cervical cancer screening].
    Liverani M, De Paola F, Danesi S, Fedriga R, Dalbuoni V, Agnoletti R, Amadori AR, Mirra F, Bonoli W, Saragoni L.
    Pathologica; 2006 Dec; 98(6):629-34. PubMed ID: 17285839
    [Abstract] [Full Text] [Related]

  • 5. Cytohistologic correlation rates between conventional Papanicolaou smears and ThinPrep cervical cytology: a comparison.
    Chacho MS, Mattie ME, Schwartz PE.
    Cancer; 2003 Jun 25; 99(3):135-40. PubMed ID: 12811853
    [Abstract] [Full Text] [Related]

  • 6. Reprocessing unsatisfactory ThinPrep Papanicolaou test specimens increases sample adequacy and detection of significant cervicovaginal lesions.
    Islam S, West AM, Saboorian MH, Ashfaq R.
    Cancer; 2004 Apr 25; 102(2):67-73. PubMed ID: 15098249
    [Abstract] [Full Text] [Related]

  • 7. Comparison of conventional Papanicolaou smears and fluid-based, thin-layer cytology with colposcopic biopsy control in central Italy: a consecutive sampling study of 461 cases.
    Rahimi S, Carnovale-Scalzo C, Marani C, Renzi C, Malvasi A, Votano S.
    Diagn Cytopathol; 2009 Jan 25; 37(1):1-3. PubMed ID: 18973131
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Cervix smears with mild atypia classified as Pap-class IIIA: results of a changed policy].
    Doornewaard H, Woudt JM, Sie-Go DM, Kooijman CD.
    Ned Tijdschr Geneeskd; 1991 Sep 07; 135(36):1642-5. PubMed ID: 1922503
    [Abstract] [Full Text] [Related]

  • 14. Comparison of conventional Papanicolaou smear and SurePath liquid-based cytology in the Copenhagen population screening programme for cervical cancer.
    Kirschner B, Simonsen K, Junge J.
    Cytopathology; 2006 Aug 07; 17(4):187-94. PubMed ID: 16879266
    [Abstract] [Full Text] [Related]

  • 15. Impact of the more restrictive definition of atypical squamous cells introduced by the 2001 Bethesda System on the sensitivity and specificity of the Papanicolaou test: a 5-year follow-up study of Papanicolaou tests originally interpreted as ASCUS, reclassified according to Bethesda 2001 criteria.
    Thrall MJ, Pambuccian SE, Stelow EB, McKeon DM, Miller L, Savik K, Gulbahce HE.
    Cancer; 2008 Jun 25; 114(3):171-9. PubMed ID: 18454461
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P, Vuorma S, Viikki M, Hakama M, Anttila A.
    BJOG; 2004 Aug 25; 111(8):842-8. PubMed ID: 15270934
    [Abstract] [Full Text] [Related]

  • 19. Adjunctive high-risk human papillomavirus DNA testing is a useful option for disease risk assessment in patients with negative Papanicolaou tests without an endocervical/transformation zone sample.
    Zhao C, Austin RM.
    Cancer; 2008 Aug 25; 114(4):242-8. PubMed ID: 18484643
    [Abstract] [Full Text] [Related]

  • 20. PAP smear after radiation therapy for cervical carcinoma.
    Rintala MA, Rantanen VT, Salmi TA, Klemi PJ, Grénman SE.
    Anticancer Res; 1997 Aug 25; 17(5B):3747-50. PubMed ID: 9427773
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.